CDXC 📈 Chromadex - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1710774076
CDXC: Dietary Supplements, NAD+ Boosters, Spirulina Extracts, Phytochemical Standards
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California. Web URL: https://www.chromadex.com
Additional Sources for CDXC Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CDXC Stock Overview
Market Cap in USD | 470m |
Sector | Consumer Defensive |
Industry | Packaged Foods |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2008-07-15 |
CDXC Stock Ratings
Growth 5y | 3.58% |
Fundamental | 7.73% |
Dividend | - |
Rel. Strength Industry | 5418 |
Analysts | 4.6/5 |
Fair Price Momentum | 5.78 USD |
Fair Price DCF | 1.35 USD |
CDXC Dividends
No Dividends PaidCDXC Growth Ratios
Growth Correlation 3m | 68.2% |
Growth Correlation 12m | 72.6% |
Growth Correlation 5y | -52.2% |
CAGR 5y | 5.04% |
CAGR/Mean DD 5y | 0.08 |
Sharpe Ratio 12m | 1.69 |
Alpha | 255.13 |
Beta | 0.88 |
Volatility | 65.53% |
Current Volume | 1204.9k |
Average Volume 20d | 751k |
What is the price of CDXC stocks?
As of December 21, 2024, the stock is trading at USD 5.49 with a total of 1,204,945 shares traded.
Over the past week, the price has changed by -10.29%, over one month by -26.80%, over three months by +51.24% and over the past year by +283.92%.
As of December 21, 2024, the stock is trading at USD 5.49 with a total of 1,204,945 shares traded.
Over the past week, the price has changed by -10.29%, over one month by -26.80%, over three months by +51.24% and over the past year by +283.92%.
Is Chromadex a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Chromadex is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.73 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDXC as of December 2024 is 5.78. This means that CDXC is currently overvalued and has a potential downside of 5.28%.
Neither. Based on ValueRay Fundamental Analyses, Chromadex is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.73 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDXC as of December 2024 is 5.78. This means that CDXC is currently overvalued and has a potential downside of 5.28%.
Is CDXC a buy, sell or hold?
Chromadex has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy CDXC.
Chromadex has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy CDXC.
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for CDXC stock price target?
According to ValueRays Forecast Model, CDXC Chromadex will be worth about 6.4 in December 2025. The stock is currently trading at 5.49. This means that the stock has a potential upside of +16.58%.
According to ValueRays Forecast Model, CDXC Chromadex will be worth about 6.4 in December 2025. The stock is currently trading at 5.49. This means that the stock has a potential upside of +16.58%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8 | 45% |
Analysts Target Price | 5.2 | -5.8% |
ValueRay Target Price | 6.4 | 16.6% |